Novo
Pfizer wins over Novo to acquire obesity start-up Metsera
Pfizer won the bidding war against Novo Nordisk to acquire Metsera, a biotech specializing in obesity drugs. The pharmaceutical giant increased its offer, valuing the startup at around $10 billion, Metsera announced Friday. In a statement, the biotech also said it received a call from the Federal Trade Commission regarding the potential risks of Novo’s […]
FDA declares Novo Nordisk drug manufacturing plant non-compliant
A troubled contract manufacturing plant in Indiana recently acquired by Novo Nordisk is considered noncompliant with Food and Drug Administration standards, a serious designation that could further delay approval of drugs made at the facility, including some from Scholar Rock and Regeneron Pharmaceuticals. STAT previously reported that an FDA inspection of the plant over the […]
Court rules against Novo Nordisk on Medicare price negotiations
A federal appeals court has unanimously rejected Novo Nordisk’s challenge to Medicare’s drug price negotiation program, a ruling that will allow the government to group products containing the same ingredient together for the purpose of choosing which drugs to negotiate. The pharmaceutical industry is on a losing streak on this issue, at least in the […]
The obesity drug of Novo Nordisk Wegovy is eliminated to treat the puree of living diseases
On Friday, the NOVO Nordisk obesity medication was eliminated on Friday by American regulators to treat an increasingly common liver disease, adding to the list of the conditions for which the therapy with superproduction is now approved. Food and Drug Administration has granted accelerated approval to Wegovy for patients with steatohepatitis associated with metabolic dysfunction, […]
Dosage questions surround Novo Nordisk Next-Gen Perous of Weight Loss
Chicago – The injection of new generation obesity of NOVO Nordisk targeting amyline hormone has shown substantial weight loss in an early study, but similar efficiency between different doses and high levels of side effects raise questions about the Novo dose in the future. In phase 1/2, the study testing the medication, called Amycretine, patients […]